C
Charles L. Sawyers
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 358
Citations - 92695
Charles L. Sawyers is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 123, co-authored 335 publications receiving 84576 citations. Previous affiliations of Charles L. Sawyers include Howard Hughes Medical Institute & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
Igor Vivanco,Charles L. Sawyers +1 more
TL;DR: Small-molecule therapeutics that block PI3K signalling might deal a severe blow to cancer cells by blocking many aspects of the tumour-cell phenotype.
Journal ArticleDOI
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker,Moshe Talpaz,Debra Resta,Bin Peng,Elisabeth Buchdunger,John Ford,Nicholas B. Lydon,Hagop M. Kantarjian,Renaud Capdeville,Sayuri Ohno-Jones,Charles L. Sawyers +10 more
TL;DR: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Journal ArticleDOI
Integrative genomic profiling of human prostate cancer
Barry S. Taylor,Nikolaus Schultz,Haley Hieronymus,Anuradha Gopalan,Yonghong Xiao,Brett S. Carver,Vivek K. Arora,Poorvi Kaushik,Ethan Cerami,Boris Reva,Yevgeniy Antipin,Nicholas Mitsiades,Thomas Landers,Igor Dolgalev,John E. Major,Manda Wilson,Nicholas D. Socci,Alex E. Lash,Adriana Heguy,James A. Eastham,Howard I. Scher,Victor E. Reuter,Peter T. Scardino,Chris Sander,Charles L. Sawyers,Charles L. Sawyers,William L. Gerald +26 more
TL;DR: Analysis of genomic and clinical outcome data from 218 prostate cancer tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score.
Journal ArticleDOI
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Mercedes E. Gorre,Mansoor Mohammed,Katharine Ellwood,Nicholas C. Hsu,Ron Paquette,P. Nagesh Rao,Charles L. Sawyers +6 more
TL;DR: It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested.
Journal ArticleDOI
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Brian J. Druker,Charles L. Sawyers,Hagop M. Kantarjian,Debra Resta,Sofia Fernandes Reese,John Ford,Renaud Capdeville,Moshe Talpaz +7 more
TL;DR: The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL.